Abstract
Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Current Signal Transduction Therapy
Title:MicroRNAs - Key Players in Haematopoiesis
Volume: 8 Issue: 1
Author(s): Stephanie Gounaris-Shannon, Sarah Newbury and Timothy Chevassut
Affiliation:
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Abstract: Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Export Options
About this article
Cite this article as:
Gounaris-Shannon Stephanie, Newbury Sarah and Chevassut Timothy, MicroRNAs - Key Players in Haematopoiesis, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010012
DOI https://dx.doi.org/10.2174/1574362411308010012 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Current Medicinal Chemistry Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Is the Expression of Deoxynucleoside Kinases and 5'-nucleotidases in Animal Tissues Related to the Biological Effects of Nucleoside Analogs?
Current Medicinal Chemistry Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Reviews on Recent Clinical Trials Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Distamycin A as Stem of DNA Minor Groove Alkylating Agents
Current Topics in Medicinal Chemistry